Renal Cell Cancer Treated with a Single-Edged Sword

Emerson Lim; Edward P. Gelmann

doi:10.1016/j.celrep.2013.02.001

Renal Cell Cancer Treated with a Single-Edged Sword

Emerson Lim
, Edward P. Gelmann

Research output: Contribution to journal › Short survey › peer-review

Abstract

Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.

Original language	English (US)
Pages (from-to)	275-276
Number of pages	2
Journal	Cell Reports
Volume	3
Issue number	2
DOIs	https://doi.org/10.1016/j.celrep.2013.02.001
State	Published - 2013
Externally published	Yes

ASJC Scopus subject areas

General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/j.celrep.2013.02.001

Cite this

@article{d14b500533af4b51aa8931573117d62e,

title = "Renal Cell Cancer Treated with a Single-Edged Sword",

abstract = "Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.",

author = "Emerson Lim and Gelmann, \{Edward P.\}",

year = "2013",

doi = "10.1016/j.celrep.2013.02.001",

language = "English (US)",

volume = "3",

pages = "275--276",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "2",

}

TY - JOUR

T1 - Renal Cell Cancer Treated with a Single-Edged Sword

AU - Lim, Emerson

AU - Gelmann, Edward P.

PY - 2013

Y1 - 2013

N2 - Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.

AB - Preclinical and early clinical data suggest that antiangiogenic treatments may lead to more aggressive tumors. In this issue of Cell Reports, Blagoev et al. (2013) show that sunitinib, a multikinase inhibitor with antiangiogenic effects, does not worsen the survival of patients with metastatic kidney cancer.

UR - https://www.scopus.com/pages/publications/84874257928

UR - https://www.scopus.com/pages/publications/84874257928#tab=citedBy

U2 - 10.1016/j.celrep.2013.02.001

DO - 10.1016/j.celrep.2013.02.001

M3 - Short survey

C2 - 23438368

AN - SCOPUS:84874257928

SN - 2211-1247

VL - 3

SP - 275

EP - 276

JO - Cell Reports

JF - Cell Reports

IS - 2

ER -

Renal Cell Cancer Treated with a Single-Edged Sword

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this